Related Experiment Video
Updated: Jan 31, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Osthole inhibits triple negative breast cancer cells by suppressing STAT3
Xuanxuan Dai1,2, Changtian Yin1,2, Yi Zhang3
1Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Background:
Triple-negative breast cancer (TNBC) is an aggressive subgroup of human breast cancer. Patients with TNBC have poor clinical outcome as they are non-responsive to current targeted therapies. There is an urgent need to identify new therapeutic targets and develop more effective treatment options for TNBC patients. Osthole, a natural product from C. monnieri, has been shown to inhibit certain cancer cells. However, the mechanisms of action as well as its effect on TNBC cells are not currently known.
Methods:
We investigated the effect of osthole in cultured TNBC cells as well as in a xenograft model of TNBC growth. We also used a high-throughput proteomics platform to identify the direct binding protein of osthole.
Results:
We found that osthole inhibited the growth of a panel of TNBC cells and induced apoptosis in both cultured cells and TNBC xenografts. We used a high-throughput proteomics platform and identified signal transducer and activator of transcription 3 (STAT3) as a potential binding protein of osthole. We further show that osthole suppressed STAT3 in TNBC cells to inhibit growth and induce apoptosis. Overexpressing STAT3 in TNBC reduced the effectiveness of osthole treatment.
Conclusions:
These results provide support for osthole as a potential new therapeutic agent for the management of TNBC. Moreover, our results indicate that STAT3 may be targeted for the development of novel anti-TNBC drugs.
Insights
Osthole, a natural compound, effectively inhibits triple-negative breast cancer (TNBC) growth and induces cell death by targeting STAT3. This suggests osthole as a promising therapeutic for TNBC management.
Area of Science:
- Oncology
- Pharmacology
- Natural Products
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis due to lack of targeted therapies.
- There is a critical need for novel therapeutic strategies against TNBC.
- Osthole, a natural product, has shown anticancer potential, but its mechanism in TNBC is unknown.
Purpose of the Study:
- To investigate the therapeutic potential of osthole against TNBC.
- To elucidate the mechanism of action of osthole in TNBC.
- To identify the molecular targets of osthole in TNBC.
Main Methods:
- Investigated osthole's effects on cultured TNBC cells and a TNBC xenograft mouse model.
- Employed high-throughput proteomics to identify osthole's direct binding protein.
- Utilized STAT3 overexpression to assess its role in osthole's efficacy.
Main Results:
- Osthole demonstrated significant inhibition of TNBC cell proliferation and induced apoptosis in vitro and in vivo.
- Signal transducer and activator of transcription 3 (STAT3) was identified as a direct binding protein of osthole.
- Osthole suppressed STAT3 activity, leading to reduced TNBC growth and apoptosis; STAT3 overexpression diminished osthole's effectiveness.
Conclusions:
- Osthole exhibits potential as a novel therapeutic agent for triple-negative breast cancer.
- Targeting STAT3 with osthole presents a promising strategy for developing new anti-TNBC drugs.
Related Concept Videos
Negative Regulator Molecules
Feedback Inhibition
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
Positive, Negative, and Zero Work
Enzyme Inhibition
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...

